My academic experience was majorly in the area of protein chemistry, specifically research in proteolytic enzymes. For high-throughput expression and purification of various proteins, I have developed a special refolding procedure for inclusion bodies produced from E. coli. My research in the Biotech industry has been focused on using the refolding technology for protein drug development, including developing p53 fusion protein for cancer therapeutics (currently a SBIR Phase II project), and recombinant plasmin based therapeutics for throbolytic therapeutic and Alzheimer's Diseases therapy. External Research Support:Current Support: Source: National Institutes of Health SBIR 1 R43 HL097388-01 TITLE: Mutant miniPlasmin for Treatment of Peripheral Arterial Occlusion PI: Xinli Lin, Ph.D. Source: National Institutes of Health SBIR 2R44 CA124001-03 TITLE: p53 Fusion Protein as an Oncology Therapeutic PI: Xinli Lin, Ph.D.Publications (selected):1. M. Lafevre-Bernt, S. Wu and X. Lin, Recombinant, refolded tetrameric p53 and gonadotropin-releasing hormone-p53 slow proliferation and induce apoptosis in p53-deficient cancer cells, Mol Cancer Ther 7 (2008), no. 6, 1420-1429.2. D. Medynski, M. Tuan, W. Liu, S. Wu and X. Lin, Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from e. Coli inclusion bodies, Protein Expr Purif 52 (2007), no. 2, 395-402.3. L. Hong, G. Koelsch, X. Lin, S. Wu, S. Terzyan, A. K. Ghosh, X. C. Zhang and J. Tang, Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor, Science 290 (2000), no. 5489, 150-153.4. X. Wang, X. Lin, J. A. Loy, J. Tang and X. C. Zhang, Crystal structure of the catalytic domain of human plasmin complexed with streptokinase, Science 281 (1998), no. 5383, 1662-1665.Specialties: Protein engineering, protein expression and refolding, protein drug development